Scholar Rock Stock Plunges 7% After Management Tempers Expectations For Early Sales Surge
Most early ISEMBYLD enrollees are expected to start infusions in 2027, management said, after the first patients began in October.
Scholar Rock Holding, which develops antibody medicines for spinal muscular atrophy and other severe neuromuscular diseases, plunged 7.39% to $47.74 in Tuesday trading, as of 11:45 AM ET, erasing $464 million in market value. On Tuesday's earnings call, management cautioned against expecting a concentrated early-year sales surge for ISEMBYLD during the company's first results update with shipment revenue.
Infusions Extend Into 2027
Management expects most early enrollees to begin infusions in 2027. That timing put the pace of ISEMBYLD's commercial launch at the heart of the results-day update.
The first shipments generated $0.6 million in revenue in the third quarter. A year earlier, Scholar Rock's net loss was $102.2 million; this quarter it reached $107.2 million.
ISEMBYLD won FDA approval in September for patients with spinal muscular atrophy who are already receiving an SMN2-targeted treatment. Patients first received infusions in October, according to the company's Tuesday launch update.
A Drop After A 22% Run-Up
Scholar Rock entered Tuesday with a 22% gain over the previous month through Monday's close. Its year-to-date advance at that close was 17%, compared with 10% for the S&P 500; both comparisons exclude Tuesday's move.
In Tuesday trading, as of 11:45 AM ET, the stock was on pace for its biggest one-day drop since October 16, 2025, and the company had a total market value of about $5.8 billion.
From Muscle Research To Commercial Sales
Scholar Rock's main experimental treatments, apitegromab and SRK-439, target activation of myostatin, a protein that limits muscle growth. Its apitegromab development program covers spinal muscular atrophy and facioscapulohumeral muscular dystrophy, which causes muscle wasting.
The company holds worldwide rights to its drug candidates and discovery platform. In 2025, it established a U.S. customer-facing team of approximately 50 professionals with neurology and rare-disease expertise to support its move toward commercial sales.
Scholar Rock said it remains on track for a European regulatory committee opinion on apitegromab in the first half of 2027.
Sources
- What Scholar Rock Holding (SRRK)'s ISEMBYLD Launch Means For Shareholders — Yahoo Finance
- BioNTech to buy Scholar Rock PRV for $205M (BNTX:NASDAQ) | Seeking Alpha — seekingalpha.com
- Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Beats Revenue Estimates — Yahoo Finance
- Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights – Company Announcement - FT.com — Financial Times
- Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘ — Yahoo Finance
- The company's filing (Scholar Rock Holding) — SEC filing
- Scholar Rock Holding — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR
